Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD.

Tan X, Harton J, Gutierrez C, Liang Y, Xie L, Muhammad C, Swift C, de Havenon A

Diabetes research and clinical practice9 Sept 2025Cited by 3 (Europe PMC)

PMID40934962DOI10.1016/j.diabres.2025.112473PepBankPUB-40934962

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
Among once-weekly GLP-1 RAs in Medicare beneficiaries with T2D and ASCVD, semaglutide had the lowest risk of all cardiovascular outcomes compared with SGLT2 inhibitors.
In plain wordsIn older US adults with diabetes and heart disease, semaglutide was linked to a lower risk of heart and vessel events than SGLT2 inhibitors.
Peptide
Semaglutide
Outcome
DecreaseCV outcomes, semaglutide vs SGLT2 inhibitors
Study
n: not reported in source
Comparator
SGLT2 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.8 to 0.85 HR
semaglutide vs SGLT2is
Source sentences
Summary
Among OW GLP-1 RAs, semaglutide had the lowest risk of all CV outcomes when compared with SGLT2is (HRs range: 0.80 to 0.85, P < 0.05 for all) and DPP-4is (HRs range: 0.58 to 0.73; P < 0.001 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cohort study using Medicare fee-for-service claims data (2006-2022).
Summary · context
Medicare beneficiaries with T2D and ASCVD treated with OW GLP-1 RAs or ONIGLTs were matched using propensity score matching.
Report a problemFND-4093496204
02HumanObservational studyEfficacy outcome
Among once-weekly GLP-1 RAs in Medicare beneficiaries with T2D and ASCVD, semaglutide had the lowest risk of all cardiovascular outcomes compared with DPP-4 inhibitors.
In plain wordsIn older US adults with diabetes and heart disease, semaglutide was linked to a lower risk of heart and vessel events than DPP-4 inhibitors.
Peptide
Semaglutide
Outcome
DecreaseCV outcomes, semaglutide vs DPP-4 inhibitors
Study
n: not reported in source
Comparator
DPP-4 inhibitors
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Hazard ratio
0.58 to 0.73 HR
semaglutide vs DPP-4is
Source sentences
Summary
Among OW GLP-1 RAs, semaglutide had the lowest risk of all CV outcomes when compared with SGLT2is (HRs range: 0.80 to 0.85, P < 0.05 for all) and DPP-4is (HRs range: 0.58 to 0.73; P < 0.001 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cohort study using Medicare fee-for-service claims data (2006-2022).
Summary · context
Medicare beneficiaries with T2D and ASCVD treated with OW GLP-1 RAs or ONIGLTs were matched using propensity score matching.
Report a problemFND-4093496205

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In Medicare beneficiaries with T2D and ASCVD, pooled once-weekly GLP-1 RAs were linked to a lower risk of cardiovascular events than other non-insulin glucose-lowering therapies.
In plain wordsIn older US adults with diabetes and heart disease, weekly GLP-1 drugs were linked to fewer heart and vessel events than other non-insulin drugs.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular events (pooled OW GLP-1 RAs)
Study
n: not reported in source
Comparator
Other non-insulin glucose-lowering therapies
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Hazard ratio
0.72 to 0.88 HR
CV events, OW GLP-1 RAs vs ONIGLTs
Source sentences
Summary
OW GLP-1 RAs were associated with reduced risk of CV events (hazard ratios [HRs] range: 0.72 to 0.88, P < 0.05 for all)
2 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cohort study using Medicare fee-for-service claims data (2006-2022).
Summary · context
Medicare beneficiaries with T2D and ASCVD treated with OW GLP-1 RAs or ONIGLTs were matched using propensity score matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4093496201
04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In Medicare beneficiaries with T2D and ASCVD, pooled once-weekly GLP-1 RAs were linked to fewer ASCVD-related total medical visits than other non-insulin therapies.
In plain wordsIn older US adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to fewer medical visits than other non-insulin drugs.
Peptide
Semaglutide
Outcome
DecreaseASCVD-related total medical visits (pooled OW GLP-1 RAs)
Study
n: not reported in source
Comparator
Other non-insulin glucose-lowering therapies
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Incidence rate ratio
0.91 IRR
ASCVD-related total medical visits
Source sentences
Summary
in addition to lower HCRU and costs including ASCVD-related total medical visits (incidence rate ratio [95 % CI]: 0.91 [0.90-0.93]; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cohort study using Medicare fee-for-service claims data (2006-2022).
Summary · context
Medicare beneficiaries with T2D and ASCVD treated with OW GLP-1 RAs or ONIGLTs were matched using propensity score matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4093496202
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In Medicare beneficiaries with T2D and ASCVD, pooled once-weekly GLP-1 RAs were linked to lower total medical costs than other non-insulin therapies.
In plain wordsIn older US adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to lower medical costs than other non-insulin drugs.
Peptide
Semaglutide
Outcome
DecreaseTotal medical costs (pooled OW GLP-1 RAs)
Study
n: not reported in source
Comparator
Other non-insulin glucose-lowering therapies
Outcome group
Healthcare costs and utilization · Whole body
Measurements
Mean cost ratio
0.88 ratio
total medical costs
Source sentences
Summary
and total medical costs (mean cost ratio [95 %CI]: 0.88 [0.86-0.91]; P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This was an observational cohort study using Medicare fee-for-service claims data (2006-2022).
Summary · context
Medicare beneficiaries with T2D and ASCVD treated with OW GLP-1 RAs or ONIGLTs were matched using propensity score matching.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4093496203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.